One randomized control trial on metformin monotherapy in advanced melanoma showed no benefit; however, the authors propose a more effective strategy would involve combining metformin with BRAF inhibitors and screening for patients with p53 polymorphisms (20). The gene discussed is BRAF; the disease is melanoma.